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2. Abstract  50 
Antimicrobial resistance (AMR) poses a threat to public health. Clinical microbiology laboratories 51 
typically rely on culturing bacteria for antimicrobial susceptibility testing (AST). As the 52 
implementation costs and technical barriers fall, whole-genome sequencing (WGS) has emerged as a 53 
‘one-stop’ test for epidemiological and predictive AST results. Few published comparisons exist for 54 
the myriad analytical pipelines used for predicting AMR. To address this, we performed an inter-55 
laboratory study providing sets of participating researchers with identical short-read WGS data 56 
sequenced from clinical isolates, allowing us to assess the reproducibility of the bioinformatic 57 
prediction of AMR between participants and identify problem cases and factors that lead to 58 
discordant results. We produced ten WGS datasets of varying quality from cultured carbapenem-59 
resistant organisms obtained from clinical samples sequenced on either an Illumina NextSeq or 60 
HiSeq instrument. Nine participating teams (‘participants’) were provided these sequence data 61 
without any other contextual information. Each participant used their choice of pipeline to 62 
determine the species, the presence of resistance-associated genes, and to predict susceptibility or 63 
resistance to amikacin, gentamicin, ciprofloxacin and cefotaxime. We found participants predicted 64 
different numbers of AMR-associated genes and different gene variants from the same clinical 65 
samples. The quality of the sequence data, choice of bioinformatic pipeline and interpretation of the 66 
results all contributed to discordance between participants. Although much of the inaccurate gene 67 
variant annotation did not affect genotypic resistance predictions, we observed low specificity when 68 
compared to phenotypic AST results but this improved in samples with higher read depths. Had the 69 
results been used to predict AST and guide treatment a different antibiotic would have been 70 
recommended for each isolate by at least one participant. These challenges, at the final analytical 71 
stage of using WGS to predict AMR, suggest the need for refinements when using this technology in 72 
clinical settings. Comprehensive public resistance sequence databases, full recommendations on 73 
sequence data quality and standardisation in the comparisons between genotype and resistance 74 
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phenotypes will all play a fundamental role in the successful implementation of AST prediction using 75 
WGS in clinical microbiology laboratories. 76 
 77 
3. Impact statement 78 
Antimicrobial resistance (AMR) is now recognised as a worldwide public health issue and identifying 79 
those infections that are resistant to common antibiotics quickly and accurately is a leading priority. 80 
The improvement of molecular methods of analysing bacterial DNA, especially whole-genome 81 
sequencing (WGS), have raised the possibility of using it as a single assay which can identify the 82 
pathogen, antibiotic susceptibility and track transmission. In this study we compared methods for 83 
predicting AMR from bacterial DNA sequences through an inter-laboratory study. This is the first 84 
study of its kind to blind sets of participants to any contextual information on the samples they were 85 
analysing and they were free to choose any analytical pipeline they wanted. This led to variation 86 
among the methods used but also variation in the results reported. Inter-laboratory studies such as 87 
these are useful as a pre-cursor to the formal external quality assurance schemes that come later 88 
when assays have been embedded into clinical service. We have shown that although there were 89 
discrepancies between results reported, these discrepancies could be traced back to problems such 90 
as sequence quality, database choice and user error, all of which can be addressed for WGS to fulfil 91 
its potential in clinical settings. 92 
 93 
4. Data summary 94 
Sequence read files for all samples used in this study have been deposited in the European 95 
Nucleotide Archive under the project accession PRJEB34513 and the following sample accession 96 
numbers: 97 
SAMEA5789893 (sample A-1), SAMEA5789894 (sample A-2), SAMEA5789895 (sample B-1), 98 
SAMEA5789896 (sample B-2), SAMEA5789897 (sample C-1), SAMEA5789898 (sample C-2), 99 
SAMEA5789899 (sample D), SAMEA5789900 (sample E), SAMEA5789901 (sample F), SAMEA5789902 100 
(sample G). 101 
The authors confirm all supporting data, code and protocols have been provided within the article or 102 
through supplementary data files. 103 
 104 
5. Introduction 105 
Antimicrobial resistance (AMR) is a major, global, public health threat with projections of up to 10 106 
million deaths per annum by 2050 [1]. The World Health Organisation’s 2015 Global Action Plan on 107 
AMR identified diagnostics as a priority area for combating resistance [2]. Currently, most diagnostic 108 
AMR testing is phenotypic antimicrobial susceptibility testing (AST) and is based on principles dating 109 
back to the early 20th century [3]. Molecular testing has facilitated the implementation of PCR assays 110 
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that target key AMR mutations and genes [4, 5]. However there remains an unmet need for truly 111 
rapid point-of-care AST [6, 7]. 112 
Whole-genome sequencing (WGS) is emerging as a routine clinical test that could be used to 113 
determine the bacterial species, undertake transmission tracking and identify multiple AMR 114 
associated mutations and genes in a single assay [8–13]. Whilst the initial clinical roll-out of WGS has 115 
used cultured bacterial isolates, metagenomics and sequencing direct from clinical samples are 116 
future possibilities [14–16]. Resolving the challenges of AMR prediction using WGS for bacteria will 117 
provide key advances for the application of metagenomics as a clinical test.  118 
There are currently a wide array of bioinformatics tools and pipelines to predict AMR from WGS data 119 
[17]. These have generally been developed by individual researchers and research groups, many 120 
with no clinical expertise, and mostly with the same basic principle of matching the input DNA 121 
sequence to entries in a reference database of known AMR-associated gene sequences. The testing 122 
of pipelines for AMR prediction is typically either performed in house [18–20] or done ad hoc for 123 
specific research [21–24]. Often, these tools are not developed with clinical application or portability 124 
in mind. Currently there are no higher-order reference materials (synthetic references that contain 125 
exact components of interest) that are available to validate these tools. Studies have reported good 126 
concordance between genotype and phenotype on datasets they have been applied to [9, 22, 25], 127 
but rarely address the factors underlying situations where different methods may produce 128 
discordant results and how this discordance should be resolved.  129 
Gaining laboratory accreditation is an important, often essential step for tests in clinical 130 
microbiology, but is less advanced for clinical bioinformatics due to its comparatively recent 131 
development. Bioinformatic reproducibility studies have been performed for clinically relevant 132 
bacterial sequence typing methods [26, 27]. However, while there have been intra-laboratory 133 
studies comparing methods of AMR prediction, there have been no comparisons of multiple 134 
methods at the inter-laboratory scale. As there is limited evidence of robust, reproducible analyses 135 
in bioinformatic prediction of AMR from clinical WGS data, adoption of these methods may be 136 
hampered in meeting the necessary accreditation. 137 
This multi-centre study used genomic DNA sequences from clinical carbapenem-resistant organisms 138 
(CROs), specifically chosen to be of varying quality and complexity, to identify the range of methods 139 
used and contributors to discordant AMR predictions. Participants included a mixture of 140 
independent individuals and teams using non-commercial AMR prediction pipelines from research 141 
groups, hospital laboratories, public health laboratories and clinical diagnostic companies. The 142 
observations made underpin our recommendations for future method developments. 143 
 144 
6. Methods 145 
6.1 Sample collection and whole genome sequencing 146 
For the purposes of this study, a panel of ten samples (A-1, A-2, B-1, B-2, C-1, C-2, D, E, F and G) were 147 
generated from seven clinical isolates (A, B, C, D, E, F and G). The bacteria were isolated between 148 
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2014 and 2017 from stool specimens from patients attending Great Ormond Street Hospital (GOSH) 149 
UK or University Hospital Galway (UHG), Ireland. They represented six clinically-relevant bacterial 150 
pathogens, including diverse Enterobacterales and also Acinetobacter baumannii, and contained six 151 
distinct families of carbapenemase genes (Table 1).  152 
Phenotypic AST was performed at UHG and GOSH using the EUCAST disk diffusion method 153 
(http://www.eucast.org) and meropenem, ertapenem, cefotaxime, amikacin, gentamicin and 154 
ciprofloxacin. The isolates were confirmed as carbapenemase producers by PCR at a reference 155 
laboratory (Public Health England).  156 
Total genomic DNA was extracted from isolate sweeps on the EZ1 Advanced XL (Qiagen) using DNA 157 
Blood 350 µl kits with an additional bead beating step. For eight samples the NEBNext Ultra II DNA 158 
Library Prep Kit (New England Biolabs) and NextSeq (Illumina) 150bp paired-end sequencing was 159 
used. For two samples Nextera DNA Library Prep Kit (Illumina) and HiSeq 100bp paired-end 160 
sequencing was used (Table 1). The FASTQ files were deposited in the European Nucleotide Archive 161 
(PRJEB34513). 162 
 163 
6.2 Inter-laboratory study plan 164 
Potential inter-laboratory participants were invited in an individual capacity both in person and by 165 
email at the meeting “Challenges and new concepts in antibiotics research”, March 2018, at Institut 166 
Pasteur, France. Fifteen individuals were also emailed directly to participate in the study. From those 167 
invited, nine sets of participants agreed to take part in the study. We will refer to these sets as 168 
‘participants’ throughout. These participants were labelled Lab_1 to Lab_9; “Lab” is used as a catch-169 
all term for an individual or team of participants, who came from a mixture of research groups, 170 
hospital laboratories, public health laboratories, and clinical diagnostic companies. All participants 171 
agreed to take part in a personal capacity using non-commercial pipelines under the condition of 172 
anonymity of the results. Each participant was not made aware who the other invited participants 173 
were at this stage.   174 
Participants were sent ten paired FASTQ files (labelled AMRIL_1 to AMRIL_10) and were blinded to 175 
their contents. The samples included: Two exact duplicates A-1 and A-2 (renamed copies of the same 176 
FASTQ files). Two duplicates with different depth of coverage B-1 and B-2 (sequenced from the same 177 
isolate, but with median read depths of 1.4X and 142.9X respectively). Two samples sequenced from 178 
the same isolate C-1 and C-2 (sequenced in two different laboratories using HiSeq and NextSeq 179 
respectively). The remaining four samples D, E, F and G represented diverse bacterial species and 180 
carbapenemases. 181 
Participants were asked to report a species identification for each pair of FASTQ files provided as 182 
well as the presence of all AMR-associated genes present in that sample. They were asked, using the 183 
above data, to make a categorical prediction on whether that sample would be resistant to 184 
ciprofloxacin, gentamicin, amikacin and cefotaxime. Lastly, participants were asked to provide a 185 
description of the analysis pipeline they used. 186 
  
 
 
 
Page 6 of 21 
AMR_WGS_CRE_revised_nocode_final.docx 
 
 187 
6.3 Participant analyses 188 
Participants returned results via an Excel spreadsheet (Supplementary File 1). Results were collated 189 
for all species identification and resistant or susceptible predictions from each participant. Collated 190 
AMR-associated genes had each name manually checked between each participant to identify minor 191 
differences in nomenclature used.  192 
Individual methods are summarised in Table 2. Briefly, all participants used a unique combination of 193 
a number of tools to analyse the samples provided and report back results. For species 194 
identification, seven participants used a combination of command line tools Kraken [28], Kraken-HLL 195 
[29], MASH [30], Centrifuge [31] and Kmerid (https://github.com/phe-bioinformatics/kmerid). Four 196 
participants also used the web-based tools WGSA (https://pathogen.watch/), BLAST 197 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) and KmerFinder 198 
(https://cge.cbs.dtu.dk/services/KmerFinder/). All participants identified species from raw reads, 199 
apart from three participants that used assembled reads (lab_2, lab_5 and lab_8). Lab_3 used both 200 
raw reads and assemblies to assign species ID using MASH and WGSA respectively. Six of the nine 201 
participating laboratories assembled the raw reads into a draft assembly before identifying AMR-202 
associated genes. Only lab_4, lab_7 and lab_9 used methods which required no assembly of the 203 
reads. Of those participants assembling their reads, SPAdes [32] was the most common assembler 204 
used with five participants either using it directly or one of two wrapper tools that contains it, 205 
Unicycler [33] or shovill (https://github.com/tseemann/shovill). Lab_5 was the only participant to 206 
use the assembler A5-miseq [34]. Lab_6 was also unique as the only participant to use a commercial 207 
bioinformatics platform, Bionumerics (Applied Maths), to perform their analysis. For the 208 
identification of AMR-associated genes ABRicate (https://github.com/tseemann/abricate) and RGI 209 
[35] were the most popular tools used and both take assembled reads as input. The other assembly 210 
based AMR gene identifiers used were c-SSTAR [36] and Resfinder 211 
(https://cge.cbs.dtu.dk/services/ResFinder/). Three tools were also used that took raw short reads 212 
as input and these were ARIBA [20], SRST2 [37] and Genefinder (https://github.com/phe-213 
bioinformatics/gene_finder). All participants used one or combination of three AMR databases in 214 
their analysis and these were CARD [35], Resfinder [18] and ARG-ANNOT [38]. The full methods, 215 
including command line parameters and software versions, can be found in Supplementary File 2. 216 
 217 
7. Results 218 
7.1 Bacterial species identification 219 
Four of the nine participants identified all species correctly from WGS data (Table 3). This included 220 
the low depth of coverage (1.4X) sample B-1 where we did not expect enough information for a 221 
correct call. Species misidentifications of D and B-2 at the genus level by Lab_5 is likely to be human 222 
reporting error rather as they correctly identified species in B-1 from a very low read depth. Lab_6 223 
used the same web-based tool for species identification as Lab_5 (Kmerfinder, CGE) but one error 224 
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was noted where raw sequence reads were inputted instead of assembled contiguous sequences 225 
(Table 3).  226 
 227 
7.2 Antimicrobial resistance gene identification 228 
We compared the number of AMR-associated genes reported by each participant in each sample 229 
and found disparities in the total reported (Figure 1). Lab_1 used two different methodologies for 230 
identifying AMR-associated genes; these are referred to as Lab_1a and Lab_1b. The number of AMR-231 
associated genes reported by each participant was affected by the choice of database used. Lab_1a, 232 
Lab_2, Lab_3 and Lab_5 all repeatedly reported the highest number of genes in each sample and all 233 
used the Comprehensive Antibiotic Resistance Database (CARD) as their reference database. This is 234 
due to CARD including many sequences from loosely AMR-associated efflux pump genes that are not 235 
found in the other databases. Lab_4 and Lab_9 also used CARD but in combination with other 236 
databases and selectively reported genes. The number of AMR-associated genes reported by each 237 
participant was also found to be associated with sequence identity and breadth of coverage 238 
thresholds used to infer a “hit”. Both Lab_2 and Lab_8 used the lowest identity and breadth of 239 
coverage thresholds (75% sequence identity and no breadth of coverage threshold) and lab_2 240 
consistently reported the highest number of AMR genes in each sample. While Lab_8 reported fewer 241 
AMR-associated genes than Lab_2, it did use ResFinder as its reference database rather than CARD, 242 
and reported the highest number of genes compared with other participants using the same 243 
database. 244 
All isolates included in this study were carbapenem resistant. The reporting of carbapenemase genes 245 
from whole-genome sequencing from all participants matched the reference PCR result in 91% of 246 
cases (91/100) (Table 4). Eight of the ten misidentifications occurred in the very low depth of 247 
coverage sample B-1 as would be expected. Differences between reported gene variants of blaIMP 248 
were seen in sample E. Five participants reported blaIMP-1, whereas the other five reported blaIMP-34. 249 
This discrepancy exactly matched the reference database used with those reported blaIMP-1 having 250 
used CARD and those who reported blaIMP-34 either having used ResFinder or ARG-ANNOT. While the 251 
sequences for blaIMP-34 included in each database are identical, the choice of blaIMP-1 reference 252 
sequence included in both databases only share 85% sequence identity. This is due to CARD’s blaIMP-1 253 
reference sequence being isolated from a Pseudomonas aeruginosa integron (NCBI accession: 254 
AJ223604) and ARG-ANNOT’s reference sequence from an Acinetobacter baumannii integron (NCBI 255 
accession: HM036079). While there is variation at the nucleotide level, both encode the same IMP-1 256 
enzyme. 257 
We compared all AMR-associated genes identified by each participant in each sample. As previously 258 
noted, the largest discrepancy were the 55 efflux pump gene sequences which were present only in 259 
CARD (Figure S1). To understand the other factors influencing discordant reporting we removed 260 
these genes that were only present in one database from our comparisons (Figure 2). A pairwise 261 
comparison between all participants found that two sets of participants only reported the exact 262 
same genes within a sample in 2% (18/900) of cases. Fourteen of these cases occurred when 263 
analysing the two identical samples (A-1 and A-2, Figure 2). Although there was little agreement 264 
  
 
 
 
Page 8 of 21 
AMR_WGS_CRE_revised_nocode_final.docx 
 
between participants for genes identified in A-1 and A-2, there was complete within-participant 265 
concordance across both samples, exhibiting reproducibility within each analysis pipeline. No two 266 
participants reported the exact same combination of gene variants in samples B-2, C-1, D, F and G. 267 
There were many clear examples where participants assigned different gene variants to the same 268 
sequence data where the reference sequences only differed by a few single nucleotides. This can be 269 
seen in Figure 2 amongst samples which contained tetracycline resistance genes (tet(A), tet(B) and 270 
tet(C)), some aminoglycoside modifying enzyme gene variants (aac(3)-IIa and aac(3)-IIc) and β-271 
lactamases (blaACT-14 and blaACT-18). We also observed differences between the same participants 272 
analysing samples from the same original isolate. Due to the very low read depth, the genes 273 
reported in B-1 bore little resemblance to B-2 across all participant results. However even in the 274 
samples from the same isolates with sufficient sequencing depth (C-1 and C-2) we observed 275 
differences in the genes identified in four out of nine participants. This suggests that resequencing, 276 
and even small increases in read length and quality, can produce variation in results. It is worth 277 
noting that all but one of these differences were additional genes identified in C-2, which had a 278 
higher read depth than B-2 (156 vs 37 median read depth). The additional genes in C-2 included 279 
ant(3’’)−Ia (Lab_2 and Lab_8), fosA7 (Lab_2 and Lab_8) and tet(C) (Lab_3) but the reported 280 
reference breadth of coverage of ant(3’’)−Ia and fosA7 was low (17% and 75%, respectively) and the 281 
sequence similarity between the purported tet(C) sequence and the reference was also low (75%). 282 
We also found no systematic differences in genes present or absent between those participants that 283 
used tools that required assembly of short reads first and those that took unassembled short reads 284 
as input (lab_4, lab_7 and lab_9, ARIBA, SRST2 and Genefinder respectively). 285 
 286 
7.3 Phenotypic and genotypic resistance concordance 287 
Given the differences in the AMR-associated genes identified in the samples by each participant, we 288 
also compared predictions of antibiotic resistance to phenotypic AST results and each other. Two 289 
participants (Lab_2 and Lab_4) did not submit any results for phenotypic resistance prediction and 290 
so were not included in the subsequent analysis. A pairwise comparison between genotypic 291 
prediction results reported by all participants, on all antibiotics and samples, showed an overall 292 
consensus of 79% (864/1092, Figure 3). This varied depending on the antibiotic tested with the 293 
highest pairwise reporting consensus of 88% (240/273) between participants for ciprofloxacin and 294 
the lowest pairwise reporting consensus of 72% (197/273) for cefotaxime, which could be 295 
understandable given the different complexities of the resistance mechanisms involved. When we 296 
compared results from each participant with the phenotypic AST results, we found an overall 297 
sensitivity of 76% and specificity of 50%. The overall number of false positives was 64/316 (20%) and 298 
overall number of false negatives was 44/316 (14%). Lab_5 had the highest number of false positives 299 
(14/40) and lowest number of false negatives (3/40), whereas Lab_1 had the lowest number of false 300 
positives (4/40) but the highest number of false negatives (7/40). Broken down by antibiotic, the 301 
highest consensus between phenotype and genotype was gentamicin (78%, 62/79) and the lowest 302 
amikacin (43% 34/79). As expected, there was little agreement between predictions within the very 303 
low read depth sample (B-1) and most participants predicted a susceptible isolate due to missing 304 
data when in fact it was resistant by phenotypic AST. However, when analysing the same isolate at 305 
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an appropriate higher read depth (B-2) there was near perfect concordance between participant 306 
reported genotypes and the resistance phenotype, with only two discrepant results reported by 307 
Lab_3 (ciprofloxacin) and Lab_7 (amikacin). Lab_3 also reported different results between the two 308 
identical samples (A-1 and A-2) where A-1 was reported as resistant and A-2 was reported as 309 
sensitive. As there were no differences in the gene content reported in either sample by this 310 
participant (Figure 2), this is likely to be due to human reporting error. We also identified a single 311 
discrepancy between amikacin resistance predicted by Lab_7 between samples C-1 and C-2 which 312 
both were sequenced from the same isolate. C-1 was reported as sensitive but C-2 was reported as 313 
resistant and the phenotypic AST result was sensitive, however there was no difference in the 314 
reported gene content in both samples by Lab_7 so it is also another likely human reporting error. 315 
Excluding the extremely low depth sample, B-1, there were only 2/30 cases where no laboratory 316 
correctly predicted the phenotypic AST result. Both of these results were an incorrect resistance 317 
prediction for amikacin in C-2 and E but as noted earlier the prediction from Lab_7 for C-2 was likely 318 
human error. 319 
 320 
8. Discussion 321 
In this study we have shown that participants using different choices of bioinformatics pipelines 322 
reported different AMR-associated gene variants when given identical mixed quality bacterial isolate 323 
WGS datasets. This led to differences in the reporting of predicted resistance phenotypes. We 324 
observed good concordance for genotypic resistance predictions between participants but poor 325 
concordance with phenotypic AST results. A similar trend has previously been seen in a study of 326 
Staphylococcus aureus genomes [39]. Concordance in phenotype prediction differed for different 327 
antibiotic classes. Good concordance was seen comparing WGS with AST results for gentamicin, but 328 
for amikacin concordance was poor. This may be due to the fact that amikacin is not affected by the 329 
action of most aminoglycoside modifying enzymes [40]. Previous studies predicting antimicrobial 330 
susceptibility from WGS data have reported sensitivities of 96% and 99% against phenotypic AST as a 331 
benchmark [21, 22], compared with an overall sensitivity of 76% in this inter-laboratory study. It 332 
should be noted however that some of the data used in this study were purposefully very low quality 333 
with some of the clinical isolates deliberately chosen to be difficult to characterise. Similar mixed 334 
quality data tested using current clinical AST phenotyping may also result in equivalent 335 
discrepancies. However, our aim here was to document the range of bioinformatics approaches 336 
being used and identify plausible contributors to discordant results reported between participants 337 
working on the same data in order to provide useful recommendations and direct future work. 338 
We identified three stages of analysis that contributed to discrepancies in predictions: the quality of 339 
the sequence data used, the bioinformatic methods (choice of database or software used) and the 340 
interpretation of those results. Where single gene calling is required (e.g. presence of a 341 
carbapenemase) results are mainly affected by sequence quality. However, once multiple genes are 342 
involved, all three analytical issues become important. We found the largest contributors to 343 
discrepant results between the gene variants reported in each sample and the phenotypic resistance 344 
predictions were the sample sequence quality, read depth and the choice of reference resistance 345 
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gene database. Samples must be sequenced to a sufficient depth as well as sufficient breadth of 346 
coverage for the expected size of the genome, usually inferred by mapping to a suitable reference 347 
genome, of at least above 90%. Based on our own experience and these results, we recommend 30X 348 
as a lower limit. This also tends to be a default setting for many read assembly tools but generally 349 
most samples should have a higher depth of coverage than this for meaningful prediction. Some 350 
participants did flag that they would not normally analyse the low depth of coverage samples (<30X, 351 
samples B-1, E and G) and if those samples are excluded from this analysis sensitivity in comparison 352 
to phenotypic AST rises from 76% to 98%. This is highly encouraging as it suggests that as long as the 353 
sequence data produced is of sufficient depth and quality (e.g. current Illumina error rates) 354 
genotypic prediction of resistance phenotype can be comparable to AST. However, we also note that 355 
many sets of participants provided little information on their employment of quality control and 356 
filtering steps. Our results therefore suggest an increased emphasis on data quality control is highly 357 
relevant to improving sensitivity.  Conversely, we have observed the choice of sequencer and DNA 358 
library preparation method has a small effect on closely related gene variants but little discernible 359 
effect on the inference of resistance phenotype. 360 
Some participants ran the same set of read data against different reference databases and merged 361 
the results which led to different gene variants being reported at the same loci. In practice different 362 
variants of the same gene may not always result in a different clinically relevant phenotype. 363 
However, we also found reference sequences in different databases for same gene variant can differ 364 
by 15% nucleotide identity (blaIMP-1 in CARD and ARG-ANNOT). If precise identification of gene 365 
variants is required, we would strongly recommend avoiding this as it effectively leads to ‘double-366 
dipping’ using the same reads. Multiple reference databases could be used but after screening for 367 
reads that have already been assigned a hit against one of the databases. This would avoid multiple 368 
different genes reported at the same genomic loci. However, it would be better to merge the 369 
different reference databases and remove the redundant sequences before comparisons are made 370 
against the test data. Sequence identity, and to lesser extent breadth of coverage cut-offs, should be 371 
kept high when comparing test data to a reference database. Based on this study we would 372 
recommend using sequence identity cut-off of at least 90%, in combination with an up to date 373 
curated reference resistance gene database. Although lowering of these thresholds does identify 374 
more candidate genes within a sample many were false negatives thus not improving concordance 375 
with phenotypic AST results in this study.  376 
There is an overwhelming need for a standardised, centralised database that integrates the current 377 
knowledge base for linking genotype with resistance phenotype and is not linked to a single research 378 
group, as previously suggested [10]. There is also a growing need regarding computational 379 
reproducibility [41, 42]. This would deal with many of the issues we have raised, such as which 380 
sequences to include and what gene nomenclature to use. With strict version control, such a 381 
resource would allow greater integration of results and be an invaluable tool for larger 382 
epidemiological studies. Currently, databases are being built for organisms such as for 383 
Mycobacterium tuberculosis, though this is a less challenging organism for genotype-phenotype 384 
predictions due to it being highly clonal and lacking an accessory genome [43, 44]. A recent 385 
publication of a new protein-based database also obtained high concordance (98.4%) between 386 
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genotype and phenotype for four food-borne pathogens [45]. However, for other clinically relevant 387 
organisms there are limited resources.  388 
Participants in this study included a mixture of individuals and teams involved in AMR prediction in a 389 
variety of settings. A potential criticism is that we did not restrict these settings to those routinely 390 
predicting AMR phenotype for clinical use, meaning that some participants were attempting 391 
analyses they did not usually perform. However, the fact that AMR phenotype prediction from WGS 392 
is not yet routine in most clinical laboratories was the very reason for undertaking this study. Clinical 393 
laboratories at the moment do not have the tools or knowledge to make good phenotypic resistance 394 
calls from genotypic data. This is evident from the fact that two participants in this study did not 395 
report any phenotypic resistance predictions as they felt they could find no valid method for doing 396 
so. At this point in time many research laboratories use these methods to track specific resistance 397 
genes or one specific resistance mechanism, rather than building tools for the broad detection of 398 
AMR in bacteria for clinical purposes. We found in this study that there was particularly low 399 
concordance between participants reporting sensitive isolates compared with phenotypic AST. The 400 
problem with the inference of phenotype from genotype is that the information is either not known 401 
at all or is expert knowledge restricted to single laboratories working on specific bacteria. In addition 402 
to this, although the identification of the presence of genes is performed in a systematic way, the 403 
prediction of resistance is still performed in an ad hoc manner by scientists and therefore subject to 404 
user error given the same set of genes. Once again M. tuberculosis is providing the first example of 405 
the need for a defined decision tree when working from the presence of genes or gene variants to 406 
the prediction of phenotypic drug resistance [46]. Interpretation and reporting of this genotypic data 407 
will need to be subjected to the same level of scrutiny as current tests if it is to form part of an 408 
accredited laboratory service within the healthcare service.  409 
A limitation of this study is that we focused on the use of short read sequence data which produces 410 
sequences far shorter than the length of genes being identified. However, we feel this is more 411 
reflective of the WGS data that is more routinely generated in clinical laboratories at this point in 412 
time. If these short reads need to be assembled into longer contiguous sequences, we found it 413 
essential to use an actively developed short read assembler such as SPAdes 414 
(http://cab.spbu.ru/software/spades/). Web-hosted tools that provide a “black box” solution to 415 
assembly and identifying resistance from uploaded WGS data should be avoided if possible, because 416 
of the lack of interpretability. Tools are needed which are open source, designed for clinical purpose 417 
and can be subjected to thorough troubleshooting when erroneous results arise [47]. To this end, 418 
permanently employed bioinformaticians are required who can provide expert interpretation of the 419 
results and update approaches as necessary. In this study, tools that either require assembled 420 
contigs (ABRicate) and those that take unassembled short reads (SRST2 and ARIBA) were capable of 421 
producing very similar results with no notable effects alone on the predication of phenotypic 422 
resistance. This hold promise for rapid phenotypic predictions as genome assembly is one of the 423 
largest bottlenecks in computational analysis time.   424 
Other limitations of this study include our focus on acquired genes rather than point mutations or 425 
many of the other resistance mechanisms found in bacteria (e.g. target site modifications and efflux 426 
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pumps). We also only required reporting on categorical resistance predictions. Furthermore, 427 
because our focus was on WGS and although we validated AST at two independent laboratories, we 428 
did not investigate potential variability and discordance in phenotypic prediction. More work needs 429 
to be done on the prediction of MICs from WGS data before it can be implemented in laboratories. 430 
This will be aided by more systematic reporting of accompanying MIC data when making WGS data 431 
available.  432 
We have outlined recommendations to improving the current state of prediction of AMR from WGS 433 
data. Some of these recommendations, such as a standardised database and better dissemination of 434 
phenotype/genotype relationships cannot be implemented immediately. However, current pipelines 435 
can be improved right now by robust quality control of starting sequence reads to make sure that 436 
genome breadth of coverage is high (>90%) and sufficient depth of coverage (>30x). We also 437 
recommended that running the same sequence read data set against multiple databases should be 438 
avoided due to the erroneous results and that sequence identity between the predicted and 439 
reference AMR genes should be higher than 90% to avoid non-specific hits. We found little 440 
difference between the results of participants depending on what reference database they chose to 441 
use, between which Illumina short read sequencer was used and whether they used assembly or 442 
assembly-free methods.  443 
In conclusion, we have identified some of the current contributors to discrepancies in predicting 444 
AMR-associated genes and phenotypes from bacterial isolate WGS data. We have provided 445 
recommendations for improving the current reporting of results. Despite its clear potential, even 446 
after accounting for poor sequence data we found that the current public methods, in particular 447 
databases, are not adequate ‘off-the-shelf’ tools for the prediction of AMR from bacterial WGS data 448 
as a universal clinical test at this point in time. 449 
 450 
9. Author statements 451 
9.1 Authors and contributors 452 
RMD, DMO’S, KAH and JFH conceived and designed the study. SDA, SB, TC, ACP, MC, EDB, MJE, EM, 453 
YM, TPTN, JP, LPS, RAS, AvB, LvD and NW all performed the initial participant analyses, and are listed 454 
in alphabetical order. Only those on the author list from participating institutions contributed to this 455 
analysis. RMD performed all secondary analyses and drafted the manuscript with assistance from 456 
DMO’S, JMG, JFH and KAH. All authors read and approved the final manuscript.   457 
 458 
9.2 Conflicts of interest 459 
ACP and AVB are employees of bioMérieux, a company developing, marketing and selling tests in the 460 
infectious disease domain. The company had no influence on the design and execution of the clinical 461 
study neither did the company influence the choice of the diagnostic tools used during the clinical 462 
study. The opinions expressed in the manuscript are the author’s which do not necessarily reflect 463 
  
 
 
 
Page 13 of 21 
AMR_WGS_CRE_revised_nocode_final.docx 
 
company policies. All other authors declare that they have no competing interests and have 464 
performed the work in an individual capacity. 465 
MJE and NW are members of PHE’s AMRHAI Reference Unit which has received financial support for 466 
conference attendance, lectures, research projects or contracted evaluations from numerous 467 
sources, including: Accelerate Diagnostics, Achaogen Inc., Allecra Therapeutics, Amplex, AstraZeneca 468 
UK Ltd, AusDiagnostics, Basilea Pharmaceutica, Becton Dickinson Diagnostics, bioMérieux, Bio-Rad 469 
Laboratories, BSAC, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, 470 
Enigma Diagnostics, ECDC, Food Standards Agency, GlaxoSmithKline Services Ltd, Helperby 471 
Therapeutics, Henry Stewart Talks, IHMA Ltd, Innovate UK, Kalidex Pharmaceuticals, Melinta 472 
Therapeutics, Merck Sharpe & Dohme Corp., Meiji Seika Pharma Co., Ltd, Mobidiag, Momentum 473 
Biosciences Ltd, Neem Biotech, NIHR, Nordic Pharma Ltd, Norgine Pharmaceuticals, Rempex 474 
Pharmaceuticals Ltd, Roche, Rokitan Ltd, Smith & Nephew UK Ltd, Shionogi & Co. Ltd, Trius 475 
Therapeutics, VenatoRx Pharmaceuticals, Wockhardt Ltd and WHO. 476 
 477 
9.3 Funding information 478 
This work was supported by the UK National Measurement System and the European Metrology 479 
Programme for Innovation and Research (EMPIR) joint research project [HLT07] “AntiMicroResist” 480 
which has received funding from the EMPIR programme co-financed by the Participating States and 481 
the European Union’s Horizon 2020 research and innovation programme. Andreu Coello Pelegrin 482 
received funding from the European Union’s Horizon 2020 research and innovation programme 483 
“New Diagnostics for Infectious Diseases” (ND4ID) under the Marie Skłodowska-Curie grant 484 
agreement N° 675412. These funding bodies had no influence on the design of the study and 485 
collection, analysis, and interpretation of data and in writing the manuscript. 486 
 487 
9.4 Ethical approval 488 
All investigations were performed in accordance with the hospitals’ research governance policies 489 
and procedures. No specific ethical approval was required, as no patient samples or identifiable data 490 
were used. The project was registered as a research study. All participants gave consent to take part 491 
in this study. 492 
 493 
9.5 Consent for publication 494 
Not applicable. 495 
 496 
  
 
 
 
Page 14 of 21 
AMR_WGS_CRE_revised_nocode_final.docx 
 
9.6 Acknowledgements 497 
The authors thank the Biomedical Scientist teams for sample collection and processing. We also 498 
thank the Pathogen Informatics Group at the Wellcome Sanger Institute for their contributions to 499 
the study. 500 
 501 
10. References 502 
1. O’Neill J. Tackling Drug-Resistant Infections Globally: final report and recommendations. 503 
https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf (2016, 504 
accessed 24 April 2019). 505 
2. World Health Organization. Global action plan on antimicrobial resistance. 506 
http://www.who.int/iris/bitstream/10665/193736/1/9789241509763_eng.pdf (2015, accessed 507 
9 May 2019). 508 
3. Fleming A. Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, 509 
with special reference to their use in the isolation of B. influenzae by Alexander Fleming, 510 
Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929. Rev Infect Dis 511 
1980;2:129–139. 512 
4. Archer GL, Pennell E. Detection of methicillin resistance in staphylococci by using a DNA probe. 513 
Antimicrob Agents Chemother 1990;34:1720–1724. 514 
5. Marlowe EM, Novak-Weekley SM, Cumpio J, Sharp SE, Momeny MA, et al. Evaluation of the 515 
Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in 516 
respiratory specimens. J Clin Microbiol 2011;49:1621–1623. 517 
6. Hays JP, Mitsakakis K, Luz S, van Belkum A, Becker K, et al. The successful uptake and 518 
sustainability of rapid infectious disease and antimicrobial resistance point-of-care testing 519 
requires a complex ‘mix-and-match’ implementation package. Eur J Clin Microbiol Infect Dis 520 
2019;38:1015–1022. 521 
7. van Belkum A, Bachmann TT, Lüdke G, Lisby JG, Kahlmeter G, et al. Developmental roadmap 522 
for antimicrobial susceptibility testing systems. Nat Rev Microbiol 2019;17:51–62. 523 
8. Török ME, Peacock SJ. Rapid whole-genome sequencing of bacterial pathogens in the clinical 524 
microbiology laboratory--pipe dream or reality? J Antimicrob Chemother 2012;67:2307–2308. 525 
9. Zankari E, Hasman H, Kaas RS, Seyfarth AM, Agersø Y, et al. Genotyping using whole-genome 526 
sequencing is a realistic alternative to surveillance based on phenotypic antimicrobial 527 
susceptibility testing. J Antimicrob Chemother 2013;68:771–777. 528 
10. Ellington MJ, Ekelund O, Aarestrup FM, Canton R, Doumith M, et al. The role of whole genome 529 
sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST 530 
Subcommittee. Clin Microbiol Infect 2017;23:2–22. 531 
  
 
 
 
Page 15 of 21 
AMR_WGS_CRE_revised_nocode_final.docx 
 
11. Tagini F, Greub G. Bacterial genome sequencing in clinical microbiology: a pathogen-oriented 532 
review. Eur J Clin Microbiol Infect Dis 2017;36:2007–2020. 533 
12. Rossen JWA, Friedrich AW, Moran-Gilad J, ESCMID Study Group for Genomic and Molecular 534 
Diagnostics (ESGMD). Practical issues in implementing whole-genome-sequencing in routine 535 
diagnostic microbiology. Clin Microbiol Infect 2018;24:355–360. 536 
13. Moran-Gilad J. How do advanced diagnostics support public health policy development? Euro 537 
Surveill;24. Epub ahead of print January 2019. DOI: 10.2807/1560-7917.ES.2019.24.4.1900068. 538 
14. Votintseva AA, Bradley P, Pankhurst L, Del Ojo Elias C, Loose M, et al. Same-day diagnostic and 539 
surveillance data for tuberculosis via whole genome sequencing of direct respiratory samples. J 540 
Clin Microbiol. Epub ahead of print 8 March 2017. DOI: 10.1128/JCM.02483-16. 541 
15. Doyle RM, Burgess C, Williams R, Gorton R, Booth H, et al. Direct whole genome sequencing of 542 
sputum accurately identifies drug resistant Mycobacterium tuberculosis faster than MGIT 543 
culture sequencing. J Clin Microbiol 2018;JCM.00666-18. 544 
16. Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, et al. Nanopore metagenomics 545 
enables rapid clinical diagnosis of bacterial lower respiratory infection. Nature Biotechnology 546 
2019;1. 547 
17. Hendriksen RS, Bortolaia V, Tate H, Tyson GH, Aarestrup FM, et al. Using Genomics to Track 548 
Global Antimicrobial Resistance. Front Public Health;7. Epub ahead of print 2019. DOI: 549 
10.3389/fpubh.2019.00242. 550 
18. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, et al. Identification of 551 
acquired antimicrobial resistance genes. J Antimicrob Chemother 2012;67:2640–2644. 552 
19. Clausen PTLC, Zankari E, Aarestrup FM, Lund O. Benchmarking of methods for identification of 553 
antimicrobial resistance genes in bacterial whole genome data. J Antimicrob Chemother 554 
2016;71:2484–2488. 555 
20. Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, et al. ARIBA: rapid antimicrobial 556 
resistance genotyping directly from sequencing reads. Microb Genom;3. Epub ahead of print 4 557 
September 2017. DOI: 10.1099/mgen.0.000131. 558 
21. Stoesser N, Batty EM, Eyre DW, Morgan M, Wyllie DH, et al. Predicting antimicrobial 559 
susceptibilities for Escherichia coli and Klebsiella pneumoniae isolates using whole genomic 560 
sequence data. J Antimicrob Chemother 2013;68:2234–2244. 561 
22. Tyson GH, McDermott PF, Li C, Chen Y, Tadesse DA, et al. WGS accurately predicts 562 
antimicrobial resistance in Escherichia coli. J Antimicrob Chemother 2015;70:2763–2769. 563 
23. Lemon JK, Khil PP, Frank KM, Dekker JP. Rapid Nanopore Sequencing of Plasmids and 564 
Resistance Gene Detection in Clinical Isolates. J Clin Microbiol 2017;55:3530–3543. 565 
  
 
 
 
Page 16 of 21 
AMR_WGS_CRE_revised_nocode_final.docx 
 
24. Greig DR, Dallman TJ, Hopkins KL, Jenkins C. MinION nanopore sequencing identifies the 566 
position and structure of bacterial antibiotic resistance determinants in a multidrug-resistant 567 
strain of enteroaggregative Escherichia coli. Microb Genom;4. Epub ahead of print 20 September 568 
2018. DOI: 10.1099/mgen.0.000213. 569 
25. CRyPTIC Consortium and the 100,000 Genomes Project, Allix-Béguec C, Arandjelovic I, Bi L, 570 
Beckert P, et al. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. 571 
N Engl J Med 2018;379:1403–1415. 572 
26. Aires-de-Sousa M, Boye K, de Lencastre H, Deplano A, Enright MC, et al. High interlaboratory 573 
reproducibility of DNA sequence-based typing of bacteria in a multicenter study. J Clin Microbiol 574 
2006;44:619–621. 575 
27. Mellmann A, Andersen PS, Bletz S, Friedrich AW, Kohl TA, et al. High Interlaboratory 576 
Reproducibility and Accuracy of Next-Generation-Sequencing-Based Bacterial Genotyping in a 577 
Ring Trial. J Clin Microbiol 2017;55:908–913. 578 
28. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact 579 
alignments. Genome Biology 2014;15:R46. 580 
29. Breitwieser FP, Baker DN, Salzberg SL. KrakenUniq: confident and fast metagenomics 581 
classification using unique k-mer counts. Genome Biol 2018;19:198. 582 
30. Ondov BD, Treangen TJ, Melsted P, Mallonee AB, Bergman NH, et al. Mash: fast genome and 583 
metagenome distance estimation using MinHash. Genome Biology 2016;17:132. 584 
31. Kim D, Song L, Breitwieser FP, Salzberg SL. Centrifuge: rapid and sensitive classification of 585 
metagenomic sequences. Genome Res. Epub ahead of print 17 October 2016. DOI: 586 
10.1101/gr.210641.116. 587 
32. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, et al. SPAdes: A New Genome 588 
Assembly Algorithm and Its Applications to Single-Cell Sequencing. Journal of Computational 589 
Biology 2012;19:455–477. 590 
33. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome assemblies from 591 
short and long sequencing reads. PLoS Comput Biol 2017;13:e1005595. 592 
34. Tritt A, Eisen JA, Facciotti MT, Darling AE. An Integrated Pipeline for de Novo Assembly of 593 
Microbial Genomes. PLOS ONE 2012;7:e42304. 594 
35. Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, et al. CARD 2017: expansion and model-595 
centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res 596 
2017;45:D566–D573. 597 
36. Man TJB de, Limbago BM. SSTAR, a Stand-Alone Easy-To-Use Antimicrobial Resistance Gene 598 
Predictor. mSphere 2016;1:e00050-15. 599 
  
 
 
 
Page 17 of 21 
AMR_WGS_CRE_revised_nocode_final.docx 
 
37. Inouye M, Dashnow H, Raven L-A, Schultz MB, Pope BJ, et al. SRST2: Rapid genomic 600 
surveillance for public health and hospital microbiology labs. Genome Medicine 2014;6:90. 601 
38. Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, et al. ARG-ANNOT, a new 602 
bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. Antimicrob 603 
Agents Chemother 2014;58:212–220. 604 
39. Mason A, Foster D, Bradley P, Golubchik T, Doumith M, et al. Accuracy of Different 605 
Bioinformatics Methods in Detecting Antibiotic Resistance and Virulence Factors from 606 
Staphylococcus aureus Whole-Genome Sequences. Journal of Clinical Microbiology 607 
2018;56:e01815-17. 608 
40. Ramirez MS, Tolmasky ME. Amikacin: Uses, Resistance, and Prospects for Inhibition. Molecules 609 
2017;22:2267. 610 
41. Garijo D, Kinnings S, Xie L, Xie L, Zhang Y, et al. Quantifying reproducibility in computational 611 
biology: the case of the tuberculosis drugome. PLoS ONE 2013;8:e80278. 612 
42. Loman N, Watson M. So you want to be a computational biologist? Nat Biotechnol 613 
2013;31:996–998. 614 
43. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, et al. Tuberculosis drug 615 
resistance mutation database. PLoS Med 2009;6:e2. 616 
44. Flandrois J-P, Lina G, Dumitrescu O. MUBII-TB-DB: a database of mutations associated with 617 
antibiotic resistance in Mycobacterium tuberculosis. BMC Bioinformatics 2014;15:107. 618 
45. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, et al. Validating the NCBI AMRFinder 619 
Tool and Resistance Gene Database Using Antimicrobial Resistance Genotype-Phenotype 620 
Correlations in a Collection of NARMS Isolates. Antimicrobial Agents and Chemotherapy 621 
2019;AAC.00483-19. 622 
46. Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, et al. A standardised method for 623 
interpreting the association between mutations and phenotypic drug resistance in 624 
Mycobacterium tuberculosis. European Respiratory Journal 2017;50:1701354. 625 
47. Balloux F, Brønstad Brynildsrud O, van Dorp L, Shaw LP, Chen H, et al. From Theory to Practice: 626 
Translating Whole-Genome Sequencing (WGS) into the Clinic. Trends in Microbiology 627 
2018;26:1035–1048. 628 
 629 
 630 
  
 
 
 
Page 18 of 21 
AMR_WGS_CRE_revised_nocode_final.docx 
 
11. Data bibliography 631 
1. Sequence read files for all samples used in this study have been deposited in the European 632 
Nucleotide Archive under the project accession PRJEB34513. 633 
 634 
12. Figures and tables 635 
12.1 Tables 636 
 637 
Table 1. Inter-laboratory study sample characteristics. 638 
Study ID Isolate species Sequencing method Carbapenemase gene 
Median depth 
of coverage 
Comment 
A-1 K. pneumoniae NEBNext Ultra II + NextSeq 150bp PE OXA-48-like 190.2 Exact duplicate of A-2 
A-2 K. pneumoniae NEBNext Ultra II + NextSeq 150bp PE OXA-48-like 190.2 Exact duplicate of A-1 
B-1 E. cloacae complex NEBNext Ultra II + NextSeq 150bp PE OXA-48-like 1.4 Very low coverage duplicate of B-2 
B-2 E. cloacae complex NEBNext Ultra II + NextSeq 150bp PE OXA-48-like 142.9 High coverage duplicate of B-1 
C-1 K. oxytoca Nextera DNA + HiSeq 100bp PE OXA-48-like 37.4 Same original isolate as C-2 
C-2 K. oxytoca NEBNext Ultra II + NextSeq 150bp PE OXA-48-like 156.4 Same original isolate as C-1 
D K. pneumoniae NEBNext Ultra II + NextSeq 150bp PE NDM 83.5  
E E. coli Nextera DNA + HiSeq 100bp PE IMP 20.6  
F C. freundii NEBNext Ultra II + NextSeq 150bp PE VIM 32.5  
G A. baumannii NEBNext Ultra II + NextSeq 150bp PE 
OXA-23-like & OXA-
51-like 
22.2  
 639 
Table 2. Summary of bioinformatic tools used for species identification and detecting antimicrobial 640 
resistance by each participant. 641 
Method 
step 
Lab_1a1 Lab_1b1 Lab_2 Lab_3 Lab_4 Lab_5 Lab_6 Lab_7 Lab_8 Lab_9 References 
Species ID Kraken-HLL Kraken-HLL BLAST 
MASH & 
WGSA 
Kraken 
KmerFinder 
(assembled 
contigs) 
KmerFinder 
(raw reads) 
Centrifuge Kraken Kmerid [28–31] 
Read 
assembly 
shovill 
(SPAdes) 
shovill 
(SPAdes) 
SPAdes 
Unicycler 
(SPAdes) 
No 
assembly 
A5-miseq 
Bionumeric
s 
No 
assembly 
Unicycler 
(SPAdes) 
No 
assembly 
[32–34] 
AMR 
identifier 
RGI c-SSTAR ABRicate 
RGI & 
Resfinder 
ARIBA RGI 
Bionumeric
s E. coli 
genotyping 
plugin 
(BLAST) 
SRST2 ABRicate Genefinder 
[18, 20, 
35–37] 
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Reference 
database 
CARD 
Resfinder & 
ARG-
ANNOT 
CARD 
CARD & 
Resfinder 
CARD & 
ARG-
ANNOT 
CARD Resfinder 
ARG-
ANNOT 
Resfinder 
CARD & 
Resfinder 
(manually 
curated) 
[18, 35, 38] 
Sequence 
identity 
cut-off 
80% 95% 75% 
80% 
(CARD) & 
90% 
(Resfinder) 
90% 80% 90% 90% 75% 90%  
Breadth 
of 
coverage 
cut-off 
0% 0% 0% 
0% (CARD) 
& 80% 
(Resfinder) 
20% 0% 60% 90% 0% 100%  
1. Lab_1 provided two sets of results with two separate methods for AMR detection and so have 642 
been split into Lab_1a and Lab_1b. 643 
 644 
Table 3. Species identification for each sample by each participant. 645 
Participant A-1 A-2 B-1 B-2 C-1 C-2 D E F G 
Reference KP KP ECl ECl KO KO KP EC CF AB 
Lab_1 KP KP ECl ECl KO KO KP EC CF AB 
Lab_2 KP KP - ECl KO KO KP EC CF AB 
Lab_3 KP KP Shigella 
phage SflV 
ECl KO KO KP EC Citrobacte
r sp. 
AB 
Lab_4 KP KP ECl ECl KO KO KP EC Citrobacte
r sp. 
AB 
Lab_5 KP KP ECl KP KO KO EC EC CF AB 
Lab_6 KP KP ECl ECl - KO Klebsiella 
sp. 
EC CF AB 
Lab_7 KP KP ECl ECl KO KO KP EC CF AB 
Lab_8 KP KP ECl ECl KO KO KP EC CF AB 
Lab_9 KP KP ECl ECl KO KO KP EC CF AB 
Missing data represent no results reported. Results highlighted in bold represent discrepancies. KP: 646 
Klebsiella pneumoniae, ECl: Enterobacter cloacae, KO: Klebsiella oxytoca, EC: Escherichia coli, CF: 647 
Citrobacter freundii, AB: Acinetobacter baumannii. 648 
 649 
Table 4. Carbapenemase genes identified for each sample by each participant and the reference 650 
laboratory PCR. 651 
Participant A-1 A-2 B-1 B-2 C-1 C-2 D E F G 
REF PCR1 OXA-48-like OXA-48-like OXA-48-like OXA-48-like OXA-48-like OXA-48-like NDM IMP VIM 
OXA-23-like 
+ OXA-51-
like 
Lab_1a2 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23 + 
OXA-66 
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Lab_1b2 OXA-48 OXA-48 OXA-48 OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23 + 
OXA-66 
Lab_2 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23 + 
OXA-66 
Lab_3 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23 + 
OXA-66 
Lab_4 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 + 
IMP-9 
VIM-4 OXA-23 + 
OXA-66 
Lab_5 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23 
Lab_6 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23 + 
OXA-66 
Lab_7 OXA-48 OXA-48 OXA-48 OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23 + 
OXA-66 
Lab_8 OXA-48 OXA-48  OXA-48 OXA-181 OXA-181 NDM-1 IMP-34 VIM-4 OXA-23 + 
OXA-66 
Lab_9 OXA-48 OXA-48 OXA-405 OXA-48 OXA-181 OXA-181 NDM-1 IMP-1 VIM-4 OXA-23 + 
OXA-66 
1. Specific carbapenemase PCR results for each sample. 652 
2. Lab_1 provided different results using two separate methods and so are included as Lab_1a and 653 
Lab_1b. 654 
Missing data represent no results reported. 655 
 656 
12.2 Figure legends 657 
 658 
Figure 1. Number of antimicrobial resistance associated genes identified in each sample by each 659 
team of participants. 660 
Figure 2. Presence of AMR-associated genes in each sample by each team of participants. Genes 661 
are organised and coloured by the class of antibiotics they are associated with resistance. Genes are 662 
only shown here if reported by more than one participant and if they were present in more than one 663 
reference database used. 664 
Figure 3. Concordance between phenotypic AST result and the genotypic prediction from WGS 665 
data. Results are presented separately for each participant, sample and antibiotic. Each tile is 666 
coloured based on whether both the resistant phenotype and genotype agreed (R/R). Both 667 
phenotype and genotype predicted sensitive (S/S). Major errors where the phenotype was sensitive 668 
but the genotype was resistant (S/R) and very major errors where the phenotype was resistant but 669 
the genotype was sensitive (R/S). Missing cells represent a result not reported. 670 
 671 
12.3 Supplementary Files 672 
Supplementary File 1: Excel spreadsheet template used by study participants to communicate 673 
results from each analysis.  674 
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Supplementary File 2: Contains supplementary methods outlining individual study participant 675 
pipelines used in data analysis and  676 
Supplementary File 3: Contains Figure S1 which shows the presence of all AMR-associated genes in 677 
each sample by each participant. Genes are organised and coloured by the class of antibiotics they 678 
are associated with resistance, or if they are associated with the efflux of multiple classes of 679 
antibiotics. 680 
 681 
